e-learning
resources
Amsterdam 2011
Sunday, 25.09.2011
Smoking-related disorders and smoking prevention
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Does smoking impair the quality of life of 34 year olds with alpha-1 antitrypsin deficiency?
L. Cano Montero, M. Nystedt- Düzakin, E. Piitulainen (Malmö, Sweden)
Source:
Annual Congress 2011 - Smoking-related disorders and smoking prevention
Session:
Smoking-related disorders and smoking prevention
Session type:
Poster Discussion
Number:
1556
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
L. Cano Montero, M. Nystedt- Düzakin, E. Piitulainen (Malmö, Sweden). Does smoking impair the quality of life of 34 year olds with alpha-1 antitrypsin deficiency?. Eur Respir J 2011; 38: Suppl. 55, 1556
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
Survival in individuals with severe alpha 1-antitrypsin deficiency (PiZZ) in comparison to a general population with known smoking habits
Source: Eur Respir J, 50 (3) 1700198; 10.1183/13993003.00198-2017
Year: 2017
Health-related quality of life in patients with alpha-1 antitrypsin deficiency
Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases
Year: 2015
Decline in health status in alpha1 antitrypsin deficiency
Source: International Congress 2017 – Current challenges in COPD evaluation
Year: 2017
Quality of life in adolescents with asthma. A five year follow up
Source: Annual Congress 2007 - Assessing asthma severity and control in children
Year: 2007
Exacerbations and duration of smoking abstinence are associated with the annual decline in lung function in individuals with PiZZ alpha-1-antitrypsin deficiency
Source: International Congress 2017 – Current challenges in COPD evaluation
Year: 2017
What influences change in health status in COPD in a seven year follow-up?
Source: International Congress 2015 – Respiratory disease management in primary care
Year: 2015
Regular fish intake during the first year of life decreases the risk of eczema in preschool age
Source: Annual Congress 2010 - Risk factors for allergic diseases in children
Year: 2010
The patient perspective of alpha-1 antitrypsin deficiency: disease burden and unmet needs
Source: Breathe, 17 (1) 200340; 10.1183/20734735.0340-2020
Year: 2021
Comparison of outcomes in augmentation naïve and augmented patients with alpha-1 antitrypsin deficiency related lung disease.
Source: International Congress 2019 – COPD clinical studies: bronchodilators, corticosteroids and more
Year: 2019
Alpha-1 antitrypsin deficiency in COPD patients: Time to count it in!
Source: Virtual Congress 2020 – Pharmacological management of COPD
Year: 2020
Trends in diagnosis and clinical presentation of alpha-1 antitrypsin deficiency within an Irish population
Source: Annual Congress 2012 - Inflammation in airway diseases: diagnosis and management
Year: 2012
The undiagnosed disease burden associated with alpha-1 antitrypsin deficiency genotypes
Source: Eur Respir J, 56 (6) 2001441; 10.1183/13993003.01441-2020
Year: 2020
Long-term experience in the treatment of alpha 1-antitrypsin deficiency: 25 years of augmentation therapy
Source: Eur Respir Rev 2015; 24: 46-51
Year: 2015
Factors associated with adherence in a population sample of 16 year old children with asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 488s
Year: 2005
Passive and active smoking during life period of asthmatics (since mother's pregnancy until the age of 28 )
Source: Eur Respir J 2003; 22: Suppl. 45, 500s
Year: 2003
Lung function at the age of 35 years in individuals with alpha-1-antitrypsin deficiency identified by neonatal screening
Source: Annual Congress 2010 - The impact of genes and environment on obstructive airway diseases
Year: 2010
Alpha 1 antitrypsin (A1AT) deficiency in children with asthma in Brazil
Source: Eur Respir J 2003; 22: Suppl. 45, 499s
Year: 2003
Diagnosing alpha-1 antitrypsin deficiency in Romania - first 1000 cases tested
Source: Virtual Congress 2020 – Asthma and COPD: How genetic and environment influences its developement?
Year: 2020
Relationship between atopy, asthma and alpha-1 antitrypsin deficiency
Source: International Congress 2019 – Clinical aspects of airway diseases
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept